Methylthioadenosine reverses brain autoimmune disease
Beatriz Moreno1, Henar Hevia, Monica Santamaria
1Neuroscience and Gene Therapy Division, Center for Applied Medical Research, University of Navarra, Navarra, Spain.
Objective:
To assess the immunomodulatory activity of methylthioadenosine (MTA) in rodent experimental autoimmune encephalomyelitis (EAE) and in patients with multiple sclerosis.
Methods:
We studied the effect of intraperitoneal MTA in the acute and chronic EAE model by quantifying clinical and histological scores and by performing immunohistochemistry stains of the brain. We studied the immunomodulatory effect of MTA in lymphocytes from EAE animals and in peripheral blood mononuclear cells from healthy control subjects and multiple sclerosis patients by assessing cell proliferation and cytokine gene expression, by real-time polymerase chain reaction, and by nuclear factor-kappaB modulation by Western blot.
Results:
We found that MTA prevents acute EAE and, more importantly, reverses chronic-relapsing EAE. MTA treatment markedly inhibited brain inflammation and reduced brain damage. Administration of MTA suppressed T-cell activation in vivo and in vitro, likely through a blockade in T-cell signaling resulting in the prevention of inhibitor of kappa B (IkappaB-alpha) degradation and in the impaired activation transcription factor nuclear factor-kappaB. Indeed, MTA suppressed the production of proinflammatory genes and cytokines (interferon-gamma, tumor necrosis factor-alpha, and inducible nitric oxide synthase) and increased the production of antiinflammatory cytokines (interleukin-10).
Interpretation:
MTA has a remarkable immunomodulatory activity and may be beneficial for multiple sclerosis and other autoimmune diseases.
Insights
Methylthioadenosine (MTA) shows significant immunomodulatory activity, preventing and reversing experimental autoimmune encephalomyelitis (EAE) in rodents. This suggests MTA may be a promising therapeutic for multiple sclerosis and other autoimmune conditions.
Area of Science:
- Neuroimmunology
- Molecular Immunology
Background:
- Experimental autoimmune encephalomyelitis (EAE) is a rodent model for multiple sclerosis (MS).
- Understanding immunomodulatory mechanisms is crucial for developing MS therapies.
Purpose of the Study:
- To evaluate the immunomodulatory effects of methylthioadenosine (MTA) in EAE.
- To assess MTA's potential in treating multiple sclerosis (MS) patients.
Main Methods:
- Administered MTA intraperitoneally in acute and chronic EAE models.
- Assessed clinical and histological scores, and performed immunohistochemistry.
- Analyzed T-cell activation, cytokine gene expression (real-time PCR), and nuclear factor-kappaB (NF-κB) pathway modulation (Western blot) in lymphocytes and peripheral blood mononuclear cells.
Main Results:
- MTA prevented acute EAE and reversed chronic-relapsing EAE, reducing brain inflammation and damage.
- MTA suppressed T-cell activation by inhibiting NF-κB signaling pathway.
- MTA decreased pro-inflammatory cytokines (IFN-γ, TNF-α, iNOS) and increased anti-inflammatory cytokine (IL-10).
Conclusions:
- MTA exhibits potent immunomodulatory activity.
- MTA demonstrates therapeutic potential for multiple sclerosis and other autoimmune diseases.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology